Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction

Vascular Health and Risk Management

Volumn 3, Issue 4, 2007, Pages 425-430

  Bissessor, Naylin ^a   White, Harvey ^b  

^a Cardiology Research Fellow   (New Zealand)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Heart failure; Left ventricular dysfunction; Myocardial infarction; Valsartan

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; BRADYKININ; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; NITRIC OXIDE; PLACEBO; RECEPTOR BLOCKING AGENT; VALSARTAN;

ANGIONEUROTIC EDEMA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; COUGHING; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG WITHDRAWAL; ELDERLY CARE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART SIZE; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; MONOTHERAPY; MORBIDITY; MORTALITY; NEPHROTOXICITY; RECOMMENDED DRUG DOSE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; SIDE EFFECT; SODIUM RETENTION; SYSTOLIC DYSFUNCTION; TASTE; TASTE DISORDER; VASOCONSTRICTION; VASODILATATION;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; HEART FAILURE; HUMANS; MYOCARDIAL INFARCTION; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; TREATMENT OUTCOME; VALINE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 35048904208     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Antman EM, Anbe DT, Armstrong PW, et al. 2004. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation, 110:588-636.
2. Asano K, Dutcher DL, Port JD, et al. 2006. Selective downregulation of the angiotensin II AT1-receptor subtype in the failing human ventricular myocardium. Circulation, 95:1193-200.
3. Chiolero A, Burnier M. 2006. Pharmacology of valsartan, an angiotensin II receptor antagonist. Expert Opin Investig Drugs, 7:1915-25.
4. Cohn JN, Tognoni G. 2001. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med, 345:1667-75.
5. Colucci WS. 2006. Pathophysiologic and clinical considerations in the treatment of heart failure: An overview. In Antman EM (ed). Cardiovascular Therapeutics. 2nd ed. Philadelphia: W.B.Saunders Company. p. 293-324.
6. Dickstein K, Kjekshus J, et al. 2002. And the OPTIMAAL Steering Committee. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction:the OPTIMAAL randomised trial. Lancet, 360:752-60.
7. Dzau VJ. 1993. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med, 153:937-42.
8. Goodfriend TL, Elliott ME, Catt KJ. 1996. Angiotensin receptors and their antagonists. N Engl J Med, 334:1649-54.
9. Hayashida W, van Eyll C, Rousseau MF, et al. 1993. Regional remodeling and nonuniform changes in diastolic function in patients with left ventricular dysfunction:modification by long-term enalapril treatment. J Am Coll Cardiol, 22:1403-10.
10. Haywood GA, Gullestad L, Katsuya T, et al. 1997. AT1 and AT2 angiotensin receptor gene expression in human heart failure. Circulation, 95:1201-6.
11. Horiuchi M, Akishita M, Dzau VJ. 1999. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension, 33:613-21.
12. Hunt SA, Baker DW, Chin MH, et al. 2001. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult:executive summary. A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol, 38:2101-13.
13. Latini R, Masson S, Anand I, et al. 2002. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure:the Valsartan Heart Failure Trial (Val-HeFT). Circulation, 106:2454-8.
14. Maggioni AP, Anand I, Gottlieb SO, et al. 2002. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol, 40:1414-21.
15. Mankad S, D'Amato TA, Reichek N, et al. 2001. Combined angiotensin II receptor antagonism and angiotensin-converting enzyme inhibition further attenuates postinfarction left ventricular remodeling. Circulation, 103:2845-50.
16. McMurray JJ, Pfeffer MA, Swedberg K, et al. 2004. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction? Circulation, 110:3281-8.
17. McMurray JJV, Ostergren J, Swedberg K, et al. 2003. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors:the CHARM-Added trial. Lancet, 362:767-71.
18. Menard J, Campbell DJ, Azizi M, et al. 1997. Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight and renin in spontaneously hypertensive rats. Circulation, 96:3072-8.
19. Mitchell GF, Lamas GA, Vaughan DE, et al. 1992. Left ventricular remodeling in the year following first anterior myocardial infarction: a quantitative analysis of contractile segment length and ventricular shape. J Am Coll Cardiol, 19:1136-44.
20. Pfeffer MA. 1995. ACE inhibition in acute myocardial infarction [editorial]. N Engl J Med, 332:118-20.
21. Pfeffer MA, McMurray J, Leizorovicz A, et al. 2000. Valsartan in Acute Myocardial Infarction trial (VALIANT):rationale and design. Am Heart J, 140:727-50.
22. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. 2003. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both [Erratum in N Engl J Med, 2004. 350:203]. N Engl J Med, 349:1893-906.
23. Rutherford JD, Pfeffer MA, Moye LA, et al. 1994. Effects of captopril on ischaemie events after myocardial infarction. Results of the survival and ventricular enlargement trial. SAVE investigators. Circulation, 90:1731-8.
24. Sioufi A, Marfil F, Jaouen A, et al. 1998. The effect of age on the pharmacokinetics of valsartan. Biopharm Drug Dispos, 19:237-44.
25. Spinale FG, de Gasparo M, Whitebread S, et al. 1997. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure. I. Effects on left ventricular performance and neurohormonal systems. Circulation, 96:2385-96.
26. Spinale FG, Mukherjee R, Iannini JP, et al. 1997. Modulation of the reninangiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure. II. Effects on myocyte contractile processes. Circulation, 96:2397-406.
27. White HD, Aylward PEG, Huang Z, et al. 2005. Mortality and morbidity remain high despite captopril and/or valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both following acute myocardial infarction:results from the Valsartan In Acute Myocardial Infarction (VALIANT) trial. Circulation, 112:3391-9.
28. Zisman LS, Asano K, Dutcher DL, et al. 1998. Differential regulation of cardiac angiotensin converting enzyme binding sites and AT1 receptor density in the failing human heart. Circulation, 98:1741.